Sunshine Biopharma Inc. - Common stock (SBFM) earnings
SBFM earnings moved a median of +0.33% by the close. Quarterly and annual SBFM reports and results, each read against the price at its own news timestamp. Back to the SBFM overview →
21 measured SBFM earnings events.
Where these SBFM earnings landedvs 21 measured SBFM earnings reactions
| Middle 50% of SBFM earnings reactions | -4.31% to +5.63% |
|---|---|
| Median reaction (to close) | +0.33% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 SBFM earnings events with a measured close landed between -4.31% and +5.63%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Sunshine Biopharma Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -2.54% | |
| Form 10-Q Sunshine Biopharma Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.59% | -16.20% | |
| Form 10-K Sunshine Biopharma Inc. For: Dec 31 | SEC filing · Form 10-K | -0.94% | +9.43% | |
| Form NT 10-K Sunshine Biopharma Inc. For: Dec 31 | SEC filing · Form NT | +1.17% | +6.31% | |
| Form 10-Q Sunshine Biopharma Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.70% | +5.63% | |
| Form 10-Q Sunshine Biopharma Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.27% | +13.64% | |
| Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year | Press release | +2.27% | +13.64% | |
| Form 10-K Sunshine Biopharma Inc. For: Dec 31 | SEC filing · Form 10-K | +1.80% | -32.43% | |
| Form NT 10-K Sunshine Biopharma Inc. For: Dec 31 | SEC filing · Form NT | +2.00% | +6.12% | |
| Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% | Press release | -2.90% | -2.90% | |
| Form 10-Q Sunshine Biopharma Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.90% | -2.90% | |
| Form 10-Q/A Sunshine Biopharma, Inc For: Jun 30 | SEC filing · Form 10-Q | -0.33% | +0.33% | |
| Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61% | Press release | +0.02% | +0.33% | |
| Form 10-Q Sunshine Biopharma, Inc For: Jun 30 | SEC filing · Form 10-Q | +0.02% | +0.33% | |
| Form NT 10-Q Sunshine Biopharma, Inc For: Jun 30 | SEC filing · Form NT | -1.27% | +2.21% | |
| Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54% | Press release | -2.54% | -11.47% | |
| Form 10-Q Sunshine Biopharma, Inc For: Mar 31 | SEC filing · Form 10-Q | -0.10% | +0.20% | |
| Form NT 10-Q Sunshine Biopharma, Inc For: Mar 31 | SEC filing · Form NT | +1.13% | +0.49% | |
| Form 10-K Sunshine Biopharma, Inc For: Dec 31 | SEC filing · Form 10-K | +11.05% | -4.31% | |
| Form 10-Q Sunshine Biopharma, Inc For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -12.41% | |
| Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition | Press release | +0.00% | -12.41% |
Keep exploring
More SBFM: analyst actions → · SEC filings → · SBFM overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SOL GLOBAL INVTS CORP (SOLCF) | 179 | 0.00% | 49% |
| Heartbeam, Inc. (BEAT) | 178 | -0.55% | 43% |
| Cardax, Inc. (CDXI) | 177 | 0.00% | 13% |
| NRC Health (NRC) | 177 | -0.16% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.